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A Standardized Approach to
Early-Phase, Proof-of-Concept
Therapeutic Trials in Dengue
This Perspective article reflects discus-
sions held at the 1st International Dengue
Therapeutics Workshop, held in Ho Chi
Minh City, Vietnam in September 2011,
attended by participants from academia
and industry, and focused on recent
experience from several randomized con-
trolled clinical trials of candidate dengue
therapeutic agents [1,2,3]. The aim of this
article is to provide an informed set of
recommendations for the design and
conduct of early-phase clinical trials where
safety and antiviral efficacy are the end-
points of interest. The focus for this article
is on early-phase testing of antiviral
therapies because this is where most drug
development efforts in academia and
industry are directed. Establishing a stan-
dardized and consistent framework for
dengue therapeutic trials will facilitate
better data management and analytical
practices and ensure that clinical data can
be readily collated and made available for
pooled analyses.
The Rationale for Dengue
Therapeutics
Dengue is a self-limiting, systemic
illness caused by any of the four dengue
viruses, DENV-1 to DENV-4, and usu-
ally resolves without complications after
3–7 days. However, in some patients a
transient vasculopathy develops between
days 3–6 of illness. Marked increases in
vascular permeability may occur in some
cases of sufficient severity to precipitate
life-threatening hypovolemic shock—i.e.
dengue shock syndrome (DSS). The
increased permeability is often accompa-
nied by thrombocytopenia and a bleed-
ing diathesis that together may result in
frank hemorrhage from mucosal sites.
Currently, there are no specific therapies
for treating dengue and management
consists of supportive care only [4,5].
Against this backdrop, development of a
therapeutic strategy that attenuates the
duration and severity of symptoms and/
or reduces the incidence or magnitude of
these major complications has become a
priority. An effective antiviral therapy
could result not only in fewer patients
requiring admission to hospital, but could
potentially also reduce transmission of
dengue viruses to mosquitoes. In recog-
nition of these possible benefits, there is
an expanding effort in academia and
industry to identify and develop novel
therapeutics for dengue.
Considerations in Clinical Trial
Design and Conduct
Patient Populations and Baseline
Features
Early-phase trials of a novel therapy
usually limit enrollment to young, other-
wise healthy adults in order to gather the
most ‘‘noise free’’ profile of drug safety.
However in high transmission settings,
dengue is primarily a disease of children
and young adults, with DSS the common-
est severe complication seen in pediatric
dengue patients. Therefore, as favorable
safety and antiviral efficacy data accumu-
late in adults, clinical development would
need to progress to include pediatric age
groups where the incidence of severe
dengue is highest.
Diagnosis
Prompt and rapid diagnosis of dengue
for potential trial participants is possible
using NS1 rapid tests [6] or RT-PCR.
DENV plasma viremia (probably a rea-
sonable surrogate marker of the underly-
ing systemic infection) typically peaks
within 24–48 h of fever onset and declines
rapidly over the ensuing days such that the
majority of patients have resolved their
viremia and are afebrile 5–7 days after
symptom onset [7,8,9]. Thus ideally diag-
nosis, screening, and enrollment; random-
ization; and commencement of treatment
with a candidate antiviral drug should all
occur within 24–48 h of fever onset.
Deciphering Drug Safety Signals
from the Natural History of Dengue
The natural history of clinical dengue
evolves through several different stages and
involves a range of clinical and laboratory
changes, some common and usually minor
(e.g. skin petechiae and thrombocytopenia)
and others rare but clinically significant
(e.g. encephalopathy or transient loss of
visual acuity) [4,5]. Distinguishing between
adverse events that are manifestations of
dengue as opposed to drug-safety signals
Citation: Simmons CP, Wolbers M, Nguyen MN, Whitehorn J, Shi PY, et al. (2012) Therapeutics for Dengue:
Recommendations for Design and Conduct of Early-Phase Clinical Trials. PLoS Negl Trop Dis 6(9): e1752.
doi:10.1371/journal.pntd.0001752
Editor: David Joseph Diemert, The George Washington University Medical Center, United States of America
Published September 27, 2012
Copyright:  2012 Simmons et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: CPS is a Wellcome Trust Senior Fellow (grant number 084368/Z/07/Z). The topic of this Perspective
article stems from clinical studies funded by Hoffmann-La Roche, USA and the Wellcome Trust. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts. Rosemary
Petric is an employee of Hoffmann-La Roche, USA. Pei-Yong Shi is an employee of the Novartis Institute of
Tropical Diseases, Singapore. Cameron Simmons is a consultant to Unither Virology LLC. The corresponding
author (CPS) takes responsibility for the content of this paper and the decision to submit for publication.
* E-mail: csimmons@oucru.org
PLOS Neglected Tropical Diseases | www.plosntds.org 1 September 2012 | Volume 6 | Issue 9 | e1752
relies on informed clinical judgment; in-
variably the best clinical judgment will be
found amongst clinicians who routinely
manage dengue cases in endemic settings.
Thus we recommend that participants in
early-phase trials should be managed as
inpatients for 5–7 study days. Follow-up
visits at days 14 and 56 should be sufficient
to observe resolution of the recognized
dengue-related clinical and laboratory ad-
verse events and to facilitate collection of
important ‘‘baseline’’ laboratory data for
each patient (see Figure 1).
Clinical and Routine Laboratory
Endpoints
During the inpatient period, routine
monitoring of body temperature and vital
signs should be conducted at least 6-hourly
and complemented with daily physical
examination and assessment of symptoms.
Routine hematological and biochemical
investigations should include the following:
daily complete blood count; serial mea-
surements of liver and renal function; and
coagulation profiles at enrollment, during
the critical phase for complications (day 4–
6 of illness), and in convalescence. Addi-
tional investigations may be indicated
depending on the known side-effect profile
of the drug under investigation. All tests
should be repeated at follow-up to estab-
lish ‘‘baseline’’ values for each patient.
Reporting of laboratory tests should focus
on measures to assess the severity of
vascular leakage (e.g. overall percentage
change in haematocrit with respect to the
baseline for that individual) as well as
thrombocytopenia, the coagulation profile,
and hepatic transaminase levels—all of
which provide useful, continuous measures
of disease evolution and severity. Daily
ultrasound to detect signs of capillary
leakage during the critical phase should
also be considered, and ideally performed
by a single experienced sonographer to
minimize interobserver variability. The
schedule of recommended clinical and
laboratory investigations is shown in
Figure 1. To allow for comparative
analyses between studies, the recom-
mended methods of reporting these vari-
ables are shown in Table 1. Although one
of the aims of therapeutic-drug develop-
ment is to prevent severe complications
such as DSS from occurring, it is unlikely
that early-phase trials in adults will be
powered to detect such an effect given the
low incidence of severe dengue in adults.
Movement into pediatric dengue case
populations will typically occur via age
de-escalation studies after acceptable safe-
ty and drug activity data has been
acquired in adults. Although the frequency
of severe complications in pediatric den-
gue cases (,4% of cases presenting to
primary health care) is higher than in
adults, large sample sizes would nonethe-
less still be required to demonstrate clinical
efficacy in preventing severe dengue.
Virological Endpoints
Plasma/serum concentrations of DENV
RNA and soluble NS1 should be mea-
sured in serial samples collected daily
during the treatment period and again at
follow-up. Infectious virus can also be
measured by classical cell culture tech-
niques, but this approach is low-through-
put and less amenable to assay validation.
The area under the log-transformed vire-
mia curve (viremia AUC) is a convenient
summary measure of the viremia in each
treatment arm (see Table 1). Survival
curve analysis of NS1 persistence should
also be reported and can be complement-
ed with quantitative measurements of NS1
changes over time. Exploratory analyses in
one study where twice-daily measurements
of viremia were undertaken [2] provided
little evidence that more frequent than
daily measurements of these virological
parameters provide greater sensitivity in
detecting differences between treatment
arms (data not shown). Genome-scale
sequencing of the virus is becoming
routine [10] and can be used to provide
baseline information on the virus popula-
tion.
Dosing and Pharmacology
The pharmacological characteristics of
the investigational product will determine
the frequency of dosing, but the total
course of therapy need not be longer than
5 days’ duration given the acute nature of
dengue. Consideration of an initial loading
dose of an antiviral drug is recommended
so as to achieve therapeutic levels at a time
when the virus-infected cell mass is at its
highest. Pharmacokinetic investigations
(e.g., Cmax, Cmin, and T1/2) during the
trial are essential to define the relationship,
if one exists, between in vivo drug
parameters and laboratory (e.g. platelet
nadir) or clinical features (e.g. frequency of
DSS) of disease. Such an understanding
should allow for further optimization of
dose and timing of therapy. Serum and, if
possible, intracellular concentrations of the
active moiety and any major metabolites
should be measured. If it is not possible to
measure the drug moiety itself then
surrogates of activity should be explored.
Examples of investigations to identify
correlates of therapy include serial mea-
surement of whole-blood gene expression
profiles, the host immune response (e.g.
cytokines, T-cell phenotypes), and phar-
macogenomics.
Non-Invasive Physiological
Monitoring
Continuous monitoring of physiologi-
cal parameters such as heart rate vari-
ability, oxygen saturation, respiratory
rate, and blood pressure appears to have
prognostic significance in the critical
care setting [11,12]. Using these tech-
niques as an observational tool within a
dengue clinical trial has the potential to
provide useful surrogates of both capil-
lary leak and treatment effect, which
could be used as endpoints in further
trials.
Sample Sizes in Early-Phase Studies
Early studies evaluating antivirals
should be randomized and powered to
detect a treatment effect on the viremia
AUC, the suggested primary endpoint. To
assess sample size requirements for such a
study, we simulated hypothetical treat-
ment effects on top of plasma viremia
curves from a previous study [3] and used
simulation based on bootstrap resampling
for our calculations. Based on these
simulations, a total of 30 patients (15 per
group) are sufficient to detect an interven-
tion effect of 0.5 log10-copies/ml per day
higher viremia clearance with 80% power
at the two-sided 5% significance level. We
consider this effect size, which can be
detected with a small trial, a reasonable
estimate of what an effective antiviral
might achieve.
Challenges for the Development of
Dengue Therapeutics
Successful therapy with an antiviral
agent is highly likely to require early
treatment in order to bring about antivi-
ral and physiological responses that are
clinically beneficial. A successful drug will
need to be rapidly bioavailable and have
pharmacological properties that deliver
rapid and potent antiviral effects in
infected tissues. One practical challenge
is that many patients with dengue cur-
rently do not present to health care
providers until they are several days into
their illness, by which time their adaptive
immune response is already beginning to
resolve their infection. In the future,
patient behavior could alter with the
availability of effective therapy. Early
therapy would also be supported by
improvements in the sensitivity of rapid
diagnostic tests, e.g. those that detect the
NS1 protein.
PLOS Neglected Tropical Diseases | www.plosntds.org 2 September 2012 | Volume 6 | Issue 9 | e1752
Figure 1. Suggested minimum schedule of assessments for a trial of a candidate therapeutic in a patient population with ,48 h of
fever at the time of commencing treatment.
doi:10.1371/journal.pntd.0001752.g001
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Summary
This article describes considerations for
the design and conduct of therapeutic
trials in dengue. We have recommended a
minimum set of clinical and laboratory
endpoints in the belief that the field will
benefit from a standardized reporting
approach. Whilst clear challenges exist in
developing therapies for dengue, not least
the self-limiting nature of the virus infec-
tion, it is hoped that the clinical trial
template described here will help acceler-
ate the clinical testing of antiviral and
other therapeutic candidates.
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Table 1. Standard analyses and reporting of clinical and virological endpoints in early-phase trials of dengue therapeutics.
Variable* Endpoint to report for each treatment arm
Adverse events Listings and summaries of adverse and severe adverse events with reference to standard definitions (e.g.
Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (Cancer Therapy Evaluation Program, NIH)).
Fever Fever clearance time—defined as the time from the start of treatment to the start of the first 24-h period
during which the tympanic or oral temperature remains below 37.5uC (with 6-hourly measurements).
Hemorrhage Proportions of patients with mild, moderate, or severe bleeding according to the following definitions:
MILD: petechiae and/or minor self-limiting mucosal bleeding that does not require an intervention (e.g.
minor nose bleeds, gum bleeds)
MODERATE: by clinical judgement, more severe skin or mucosal bleeding but not requiring a transfusion or
fluid resuscitation (e.g. small haematemesis or widespread bruising/ecchymoses)
SEVERE: bleeding causing haemodynamic compromise requiring fluid resuscitation or use of blood products;
any intracranial bleed (regardless of need for fluids); any bleed causing death
Virological features Area under the log-transformed viremia curve from first dose to the end of study day 7 (AUC)a
Time to resolution of viremia (,1000 copies/ml)a
Time to resolution of plasma NS1 antigenemia—defined as the first time NS1 becomes undetectable in
plasma
Capillary permeability Maximum % hemoconcentration—determined by comparison of the maximum Hct detected in the acute
phase and a baseline measurement or an age/gender matched population value
Hematology Minimum platelet count during the critical phase
Maximum aPTT during the critical phase
Maximum INR during the critical phase
Minimum fibrinogen during the critical phase
Biochemistry Highest hepatic transaminase levels (AST/ALT)
*Comparisons of laboratory and virological features between study groups should be adjusted for the baseline value, the day of illness on admission, and serotype/
serology (for virological features) to maximize power.
aAUC calculated based on the trapezoidal rule with values below the limit of detection replaced by half of the detection limit.
doi:10.1371/journal.pntd.0001752.t001
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